Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.50 |
| ▸ | AR | P10275 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494178 | 1.00 | CRBN (0.58) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL29841399 | 1.00 | CRBN (0.58) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL22645400 | 0.93 | CRBN (0.54) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL29841424 | 0.88 | CRBN (0.54) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL24734969 | 0.88 | CRBN (0.54) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL24735571 | 0.88 | IRAK4 (0.51) | CRBNBTKHPGDSDDB1 | |
| SCHEMBL29841322 | 0.88 | IRAK4 (0.51) | CRBNBTKHPGDSDDB1 | |
| SCHEMBL20046645 | 0.88 | CRBN (0.46) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL20076100 | 0.88 | CRBN (0.46) | CRBNBTKHPGDSDDB1AR | |
| SCHEMBL22661369 | 0.87 | CRBN (0.65) | CRBNBTKHPGDSDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | CRBN 692/4885BTK 1/4885HPGDS 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.